Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Current Liabilities data on file, last reported at $325.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $325.0 million, up 11.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $325.0 million (up 11.43% YoY), and the FY2025 annual result was $384.0 million, up 11.63% from the prior year.
• Total Current Liabilities declined to $325.0 million in Q1 2026 per RARE's latest filing, from $384.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $384.0 million in Q4 2025 and troughed at $167.2 million in Q1 2022.
• A 5-year average of $273.8 million and a median of $272.9 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 73.64% in 2022, then increased 7.36% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $261.2 million in 2022, then gained by 7.36% to $280.4 million in 2023, then grew by 22.67% to $344.0 million in 2024, then increased by 11.63% to $384.0 million in 2025, then declined by 15.36% to $325.0 million in 2026.
• Business Quant data shows RARE's Total Current Liabilities at $325.0 million in Q1 2026, $384.0 million in Q4 2025, and $340.0 million in Q3 2025.